Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Rigel Pharmaceuticals is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Rigel Pharmaceuticals employs 165 staff and has a trailing 12-month revenue of around $85.9 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $1.91 |
|---|---|
| 52-week range | $0.64 - $3.52 |
| 50-day moving average | $1.14 |
| 200-day moving average | $1.41 |
| Wall St. target price | $3.66 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.50 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.91 from 2023-01-25
| 1 week (2023-01-20) | -4.50% |
|---|---|
| 1 month (2022-12-27) | 54.03% |
| 3 months (2022-10-27) | 169.01% |
| 6 months (2022-07-27) | 50.39% |
| 1 year (2022-01-25) | -21.40% |
|---|---|
| 2 years (2021-01-27) | -46.05% |
| 3 years (2020-01-27) | 2.46 |
| 5 years (2018-01-26) | 4.32 |
| Revenue TTM | $85.9 million |
|---|---|
| Gross profit TTM | $72.4 million |
| Return on assets TTM | -32.7% |
| Return on equity TTM | -553.79% |
| Profit margin | -96.21% |
| Book value | $-0.12 |
| Market capitalisation | $331 million |
TTM: trailing 12 months
We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.
Rigel Pharmaceuticals's shares were split on a 1:9 basis on 25 June 2003. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.
Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $0.64 up to $3.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 0.736. This would suggest that Rigel Pharmaceuticals's shares are less volatile than average (for this exchange).
Rigel Pharmaceuticals, Inc. , a biotechnology company, engages in discovering, developing, and providing small molecule drugs that enhance the lives of patients with hematologic disorders, cancer, and rare immune diseases. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, its other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. Rigel Pharmaceuticals, Inc.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
We explore some of the best brokerage accounts for international stock trading. Here’s what you need to know.
